---
title: "Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Clinical trials questions"
description: "Clinical trials questions on Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Subgroup results. Questions: How were the Vabysmo wet AMD trials (TENAYA and LUCERNE) designed? How well does Vabysmo work vs aflibercept for wet AMD (TENAYA, LUCERNE)? Were Vabysmo wet AMD results consistent across age, sex, race, and baseline vision? How many wet AMD patients were on Vabysmo every 16 weeks at week 48? 1 further question follow. 5 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Clinical trials questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)

Questions that apply to every indication of Vabysmo are on [Vabysmo (faricimab-svoa), all indications](https://www.evicenter.com/medical-information/vabysmo).

## Clinical trials

<a id="vabysmo-tenaya-lucerne-design"></a>

### How were the Vabysmo wet AMD trials (TENAYA and LUCERNE) designed?

> “The safety and efficacy of VABYSMO were assessed in two randomized, multi-center, 
> double-masked, active comparator-controlled, 2-year studies (TENAYA – NCT03823287 and 
> LUCERNE – NCT03823300) in patients with nAMD.”

Source: [VABYSMO: Prescribing information, page 15, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=15)

> “A total of 1,329 newly diagnosed, treatment-naïve patients were enrolled in these studies, and 
> 664 patients received at least one dose of VABYSMO. Patient ages ranged from 50 to 99 with a 
> mean of 75.9 years. The studies were identically designed two year studies. Patients were 
> randomized in a 1:1 ratio to one of two treatment arms: 1) aflibercept 2 mg administered fixed 
> every 8 weeks (Q8W) after three initial monthly doses; and VABYSMO 6 mg (0.05 mL of 120 
> mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ±”

Source: [VABYSMO: Prescribing information, page 15, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=15)

> “7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual 
> acuity evaluations 8 and 12 weeks later to determine whether to give a 6 mg (0.05 mL of 120 
> mg/mL solution) dose via intravitreal injection on one of the following three regimens: 1) Weeks 
> 28 and 44; (also referred to as Q16W dosing); 2) Weeks 24, 36 and 48 (also referred to as Q12W 
> dosing); or 3) Weeks 20, 28, 36 and 44 (also referred to as Q8W dosing). However, the utility of 
> these criteria to guide dosing intervals has not been established.”

Source: [VABYSMO: Prescribing information, page 16, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=16)

> “Patients were assigned to Q8W (week 20) or Q12W (week 24) if ANY disease activity criteria were met.<sup>1,2</sup>”

Source: [VABYSMO: Study Design in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/efficacy/study-design-namd.html#:~:text=Patients%20were%20assigned%20to%20Q8W,ANY%20disease%20activity%20criteria%20were)

> “At week 24 only, investigator opinion of significant nAMD activity that requires immediate treatment would qualify as active disease and trigger assignment to fixed Q12W interval.<sup>2</sup>”

Source: [VABYSMO: Study Design in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/efficacy/study-design-namd.html#:~:text=At%20week%2024%20only%2C%20investigator,trigger%20assignment%20to%20fixed%20Q12W)

Note: The second Prescribing Information passage continues the sentence that ends the first, across a page break of the label.

## Study results

<a id="vabysmo-namd-vision-vs-aflibercept"></a>

### How well does Vabysmo work vs aflibercept for wet AMD (TENAYA, LUCERNE)?

> “Both studies demonstrated non-inferiority to the comparator control (aflibercept) at the primary 
> endpoint, defined as the mean change from baseline in Best Corrected Visual Acuity (BCVA) 
> when averaged over the week 40, 44, and 48 visits and measured by the Early Treatment 
> Diabetic Retinopathy Study (ETDRS) letter chart. The primary endpoint analysis was a non- 
> inferiority comparison for the mean change in BCVA between the aflibercept and the 
> VABYSMO arm. The lower bound of the 95% confidence interval for the mean change in 
> BCVA could not be lower than minus 4 letters to declare non-inferiority. In both studies, 
> VABYSMO treated patients had a non-inferior mean change from baseline in BCVA compared 
> to patients treated with aflibercept. Detailed results of both studies are shown in Table 2, Figure 
> 1, and Figure 2 below. The clinical efficacy for the second year of the study has not been 
> reviewed.”

Source: [VABYSMO: Prescribing information, page 16, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=16)

> “Table 2: Primary Endpoint Results<sup>a</sup> in the TENAYA and LUCERNE Studies 
>
> TENAYA 
> LUCERNE 
> VABYSMO  
> N = 334 
> Aflibercept 
> N = 337 
> VABYSMO 
> N = 331 
> Aflibercept 
> N = 327 
> Mean change in BCVA 
> as measured by ETDRS 
> letter score from baseline 
> (95% CI) 
> 5.8 
> (4.6, 7.1) 
> 5.1 
> (3.9, 6.4) 
> 6.6 
> (5.3, 7.8) 
> 6.6 
> (5.3, 7.8) 
> Difference in LS mean 
> (95% CI) 
> 0.7 
> (-1.1, 2.5) 
>
> 0.0 
> (-1.7, 1.8) 
>
> <sup>a</sup> Average of weeks 40, 44 and 48 
> BCVA: Best Corrected Visual Acuity  
> ETDRS: Early Treatment Diabetic Retinopathy Study  
> CI: Confidence Interval 
> LS: Least Square”

Source: [VABYSMO: Prescribing information, page 17, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=17)

> “VABYSMO met its primary endpoint of non-inferiority vs aflibercept 2 mg in the mean change from baseline in BCVA at year 1 (avg. of weeks 40, 44, and 48).<sup>1</sup>”

Source: [VABYSMO: Vision Data in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/efficacy/vision-namd.html#:~:text=VABYSMO%20met%20its%20primary%20endpoint%20of%20non%2Dinferiority%20vs%20aflibercept%202%20mg%20in,-the%20mean%20change)

> “Primary endpoint was measured by the ETDRS letter score and tested for non-inferiority using a margin of 4 letters. Differences in LS means for VABYSMO were +0.7 letters (CI: [95%] -1.1, +2.5) in TENAYA; and 0.0 letters (CI: [95%] -1.7, +1.8) in LUCERNE.<sup>1</sup>”

Source: [VABYSMO: Vision Data in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/efficacy/vision-namd.html#:~:text=Primary%20endpoint%20was%20measured%20by,%28CI%3A%20%5B95%25%5D%20%2D1.7%2C%20%2B1.8%29%20in)

Note: Table 2 columns are VABYSMO and aflibercept in TENAYA, then VABYSMO and aflibercept in LUCERNE, in that order.

<a id="vabysmo-namd-dosing-interval-results"></a>

### How many wet AMD patients were on Vabysmo every 16 weeks at week 48?

> “At week 48, after 4 initial monthly doses in the VABYSMO arm, 45% of patients received the  
> Weeks 28 and 44 dosing, 33% of patients received the Weeks 24, 36 and 48 dosing, and the 
> remaining 22% of patients received dosing every 8 weeks. These percentages are reflective of 
> what happened within the conduct of these trials and indicate that some patients did well on two 
> (2) doses spaced 16 weeks apart, or three (3) doses spaced 12 weeks apart, but the percentages 
> may not be generalizable to a broader nAMD population for a variety of reasons. The 
> inclusion/exclusion criteria limited enrollment to a select subset of treatment-naïve, newly 
> diagnosed nAMD patients and there is no empirical data that a similar magnitude would be 
> observed if eligibility criteria allowed for broader enrollment. The disease activity criteria, which 
> was instrumental in determining dose frequency, is unvalidated. Stricter criteria would have 
> changed how patients were treated resulting in different percentages of subjects in each dose 
> interval cohort. There was not a similarly dosed aflibercept arm for comparison, which makes the 
> percentages difficult to interpret.”

Source: [VABYSMO: Prescribing information, page 16, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=16)

> “Q16W=weeks 28 and 44; Q12W=weeks 24, 36, and 48; Q8W=weeks 20, 28, 36, and 44.<sup>1</sup>”

Source: [VABYSMO: Durability Data in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/efficacy/durability-namd.html#:~:text=Q16W%3Dweeks%2028%20and%2044%3B%20Q12W%3Dweeks,Q8W%3Dweeks%2020%2C%2028%2C%2036%2C%20and)

<a id="vabysmo-namd-retinal-thickness"></a>

### Does Vabysmo reduce retinal thickness (CST) in wet AMD trials?

> “Reductions 
> in CST were observed across all treatment arms throughout the six Phase 3 studies in nAMD, 
> DME, and RVO.”

Source: [VABYSMO: Prescribing information, page 14, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=14)

> “Reduction in CST (ILM-RPE) over time was a prespecified secondary endpoint.<sup>2</sup>
>
> P values (for superiority testing) are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P values.
> Clinical significance has not been established, and conclusions regarding treatment effect cannot be drawn.”

Source: [VABYSMO: Drying Data in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/efficacy/drying-namd.html#:~:text=Reduction%20in%20CST%20%28ILM%2DRPE%29%20over,treatment%20effect%20cannot%20be%20drawn.)

Note: The drying page of the VABYSMO HCP site presents the nAMD central subfield thickness (CST) results as a graph; the quoted text is the assessment and limitations statement printed with it.

## Subgroup results

<a id="vabysmo-namd-subgroups"></a>

### Were Vabysmo wet AMD results consistent across age, sex, race, and baseline vision?

> “Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline visual acuity) in each 
> study were consistent with the results in the overall population.”

Source: [VABYSMO: Prescribing information, page 18, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=18)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)
- [Indication](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/indication)
- [Safety](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/dosing-and-administration)
